Federal Preemption Defenses (Medical Devices, Generic Drugs)
Published 15 authorities named
Federal preemption can end a Georgia product claim even if the product hurt someone, but its reach depends on the product and the federal rule. A premarket-approved device and a generic drug’s label get strong protection. A brand-name drug’s label and a device cleared as substantially equivalent get far less. So the first questions are which federal path the product took, and exactly what the state claim would require.
The map
| Product | Federal rule | Leading case | State claim that survives |
|---|---|---|---|
| Device with premarket approval | 21 U.S.C. § 360k | Riegel v. Medtronic (2008) | One that parallels federal requirements |
| Device cleared through 510(k) | 21 U.S.C. § 360k | Medtronic v. Lohr (1996) | The ordinary claims in that case survived |
| Generic drug, warning | Same-label rule | PLIVA v. Mensing (2011) | Not a label-based claim |
| Generic drug, design | Same-label rule | Mutual Pharmaceutical v. Bartlett (2013) | Not one that turns on warnings |
| Brand-name drug, warning | No express clause | Wyeth v. Levine (2009) | Most, absent clear evidence |
| Pesticide | 7 U.S.C. § 136v(b) | Bates v. Dow Agrosciences (2005) | One with parallel requirements |
| Vehicle equipment | Safety Act and FMVSS | Geier (2000); Williamson (2011) | Depends on the standard |
Claims that the company defrauded the agency are their own category. In Buckman v. Plaintiffs’ Legal Committee, 531 U.S. 341 (2001), the Court held that “state-law fraud-on-the-FDA claims conflict with, and are therefore impliedly pre-empted by federal law”.
Devices: express preemption
The statute bars any state requirement “which is different from, or in addition to” a federal device requirement. Riegel v. Medtronic, 552 U.S. 312 (2008), applied that to a catheter with premarket approval, and common law duties counted as requirements. But the Court added that § 360k “does not prevent a State from providing a damages remedy for claims premised on a violation of FDA regulations”, because such duties “parallel” federal ones.
Medtronic v. Lohr, 518 U.S. 470 (1996), went the other way on a device reviewed for substantial equivalence. The Court said that review “is by no means comparable to the PMA process”. The practical steps are on defective medical devices.
Drugs: a split between brand and generic
Everything turns on who can change the label.
Generic. In PLIVA v. Mensing, 564 U.S. 604 (2011), the manufacturers faced state duties to use a safer label, but federal law requires that generic labels be the same as the brand’s. Compliance with both was impossible. Mutual Pharmaceutical v. Bartlett, 570 U.S. 472 (2013), held that “state-law design-defect claims that turn on the adequacy of a drug’s warnings are pre-empted”, and it rejected the argument that the company could simply stop selling.
Brand-name. Wyeth v. Levine, 555 U.S. 555 (2009), went the other way because a brand company can strengthen its label under FDA’s changes-being-effected rule. Preemption requires “clear evidence that the FDA would not have approved a change”. Merck v. Albrecht, 587 U.S. 299 (2019), defined that: the company fully informed the FDA of the justifications for the warning, and the FDA told the company it wouldn’t approve the change. The Court also said the question is “one for a judge to decide, not a jury”.
These decisions are narrower than a slogan. Mensing and Bartlett address labels and warning-based design claims. A claim that a batch departed from approved specifications isn’t what they decided, so have counsel read it against the facts. Pharmaceutical claims carries this further.
Pesticides
Bates v. Dow Agrosciences, 544 U.S. 431 (2005), adopted a “parallel requirements” reading of FIFRA. Banks v. ICI Americas, 264 Ga. 732 (1994), had affirmed that a label claim was preempted, and it should be read with Bates. Georgia has since added its own rule. Under SB 144 (2025), § 2-7-171, starting January 1, 2026, an EPA-approved pesticide label “shall be deemed a sufficient warning label” under state duty-to-warn law, unless the EPA has determined that a manufacturer knowingly withheld, concealed, misrepresented, or destroyed material information. Check the codified version for the final wording.
Vehicles
The Safety Act has both a preemption clause and a saving clause: “[c]ompliance with” a federal standard “does not exempt any person from any liability under common law”. Geier v. American Honda, 529 U.S. 861 (2000), still found preempted a claim that a 1987 car needed an airbag. Williamson v. Mazda, 562 U.S. 323 (2011), held that FMVSS 208 “does not pre-empt state tort suits claiming that manufacturers should have installed lap-and-shoulder belts, instead of lap belts, on rear inner seats”.
That matters in Georgia. Parks v. Hyundai, 294 Ga. App. 112 (2008), found impliedly preempted a similar claim about a center rear seat, and it came three years before Williamson. Read the two together. Georgia’s Parks also shows that a specific design of the installed belt may stay outside preemption. Defective vehicles has more.
Working through a preemption defense
- Identify the path. Pull the FDA, EPA, or NHTSA record for this model, not its product family.
- Name the state duty. Write out what the claim would require the company to have done.
- Compare them. Different or additional? Parallel? Or impossible to do both?
- Find the violation. A parallel claim needs a specific federal requirement that was breached.
- Look at timing. Which version of the federal rule applied when this unit was made?
- Consider other defendants and theories. Preemption may not cover every party or every kind of claim.
A preemption ruling can come early, at a motion to dismiss, and a federal court may hear the question if the case is removed. So do this analysis before filing. Georgia’s own limits still apply if a claim survives, including the ten-year repose and the two-year period in § 9-3-33.
Sources
- Buckman v. Plaintiffs’ Legal Committee, 531 U.S. 341
- 21 U.S.C. § 360k
- Riegel v. Medtronic, 552 U.S. 312
- Medtronic v. Lohr, 518 U.S. 470
- PLIVA v. Mensing, 564 U.S. 604
- Mutual Pharmaceutical v. Bartlett, 570 U.S. 472
- Wyeth v. Levine, 555 U.S. 555
- Merck v. Albrecht, 587 U.S. 299
- Bates v. Dow Agrosciences, 544 U.S. 431
- Banks v. ICI Americas, 264 Ga. 732
- Georgia Senate Bill 144 (2025)
- Geier v. American Honda, 529 U.S. 861
- Williamson v. Mazda, 562 U.S. 323
- Parks v. Hyundai, 294 Ga. App. 112
- Official Code of Georgia Annotated, November 2022 public release: §§ 9-3-33, 51-1-11
This page was last reviewed in November 2026 for general information. Laws and court decisions can change after that date. It is not legal advice and does not create an attorney-client relationship.
Authorities cited
Georgia code
- O.C.G.A. § 2-7-171
- O.C.G.A. § 9-3-33
- O.C.G.A. § 51-1-11
Court decisions
- Buckman v. Plaintiffs’ Legal Committee, 531 U.S. 341
- Riegel v. Medtronic, 552 U.S. 312
- Medtronic v. Lohr, 518 U.S. 470
- PLIVA v. Mensing, 564 U.S. 604
- Mutual Pharmaceutical v. Bartlett, 570 U.S. 472
- Wyeth v. Levine, 555 U.S. 555
- Merck v. Albrecht, 587 U.S. 299
- Bates v. Dow Agrosciences, 544 U.S. 431
- Banks v. ICI Americas, 264 Ga. 732
- Geier v. American Honda, 529 U.S. 861
- Williamson v. Mazda, 562 U.S. 323
- Parks v. Hyundai, 294 Ga. App. 112
Leave a Reply